Clinical Trials Logo

Short Bowel Syndrome clinical trials

View clinical trials related to Short Bowel Syndrome.

Filter by:

NCT ID: NCT03663582 Recruiting - Clinical trials for Short Bowel Syndrome

Study of Teduglutide in Japanese Participants With Short Bowel Syndrome

Start date: November 1, 2018
Phase: Phase 3
Study type: Interventional

The objectives of this clinical study are to evaluate the safety, efficacy, and pharmacokinetics (PK) of teduglutide in Japanese participants with short bowel syndrome (SBS) who are dependent on parenteral nutrition/intravenous (PN/IV) over a 24-week treatment period.

NCT ID: NCT03596164 Enrolling by invitation - Clinical trials for Short Bowel Syndrome

An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004

Start date: July 9, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this clinical study is to evaluate the long-term safety and efficacy of teduglutide in Japanese participants with PN/IV (parenteral nutrition/intravenous)-dependent SBS (short bowel syndrome) who completed SHP633-306 or who were in the extension phase of the TED-C14-004 (NCT02340819) study.

NCT ID: NCT03582384 Not yet recruiting - Clinical trials for Short Bowel Syndrome

Use of Tocofersolan (Vedrop®) to Prevent or Treat Refractive Vitamin E Deficiency in Infants and Children

Start date: August 2018
Phase: Phase 2
Study type: Interventional

Patients with short bowel syndrome or other forms of intestinal failure/fat malabsorption are unable to tolerate adequate oral or enteral feedings. They require that nutrition be given as enteral nutrition that is delivered by feeding tube. Often these children take supplements such as vitamins to help improve their nutritional status but, due to their condition, they have difficulty absorbing the supplement sufficiently and most of it is lost in the stool. The drug that will be studied, Tocofersolan (Vedrop®) is a form of vitamin E, a type of the fat soluble vitamin needed in the human diet. It has been formulated in such a way that it may be more easily absorbed by patients with this condition. The main purpose of the study is to learn about the safety and tolerability of this form of vitamin E. Before receiving the study drug, the severity of the child's vitamin E deficiency will be determined by a blood sample, followed by giving them a daily dose of tocofersolan (Vedrop®) either orally or through their feeding tube. After a 4 weeks of therapy, a second blood sample will be checked and the child will continue either same dose of tocoferssolan or it will be adjusted in response to the blood levels. If the study drug works as it is designed to do, there should be an increase in the concentration of the vitamin E in the child's blood, suggesting that the drug was absorbed. At each visit, a sample of blood will be obtained to assess the child's vitamin E status and general health. Patients will remain on tocofersolan for approximately one year or as long as the study remains open. Based on the European pediatric experience, patients should be expected be on tocofersolan a minimum of 3 months, ideally 6 months to see optimal clinical response.

NCT ID: NCT03571516 Recruiting - Clinical trials for Short Bowel Syndrome

Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome

Start date: August 6, 2018
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the safety, efficacy/pharmacodynamics (PD) and pharmacokinetics (PK) of teduglutide treatment in infants with short bowel syndrome (SBS) dependent on parenteral (PN) support.

NCT ID: NCT03562130 Not yet recruiting - Clinical trials for Short Bowel Syndrome

Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients

REVE
Start date: June 2018
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate if the treatment could maximize intestinal absorption, minimize the inconvenience of diarrhea, and avoid, reduce or eliminate the need for parenteral support (PS) to achieve normal growth, to avoid parenteral nutrition complications and to achieve the best possible quality of life for the patient

NCT ID: NCT03530852 Not yet recruiting - Clinical trials for Short Bowel Syndrome

A 90 Day, Phase 4,Open Labeled Exploratory Study of RELiZORB

Start date: August 15, 2018
Phase: N/A
Study type: Interventional

Children with inadequate intestinal absorption due to loss of large amounts of small bowel require intravenous nutrition (feeding through the vein) to sustain hydration and nutrition to avoid starvation and dehydration; however, intravenous (IV) nutrition can lead to complications including liver failure. Tube feeding directly to the small intestine avoids the complications of IV nutrition, but fats are not fully digestible due to inadequate bowel function. We propose to predigest the fat using a small cartridge attached to the feeding tube to allow for rapid absorption with the possibility of reducing or eliminating the need for intravenous nutrition

NCT ID: NCT03451253 Recruiting - Clinical trials for Inflammatory Bowel Diseases

Effects of an Amino Acid Mixture on Gastrointestinal Function, Inflammation and Fluid Balance: A Pilot Study in Patients With Inflammatory Bowel Disease

Start date: April 12, 2018
Phase: N/A
Study type: Interventional

This pilot study will examine the benefit of this amino acid based hydration solution in patients with IBD who have undergone a total colectomy and have either ileostomies or jpouches. Findings from this study and possible future studies could have broad implications for patients with malabsorption resulting from many underlying conditions, including IBD.

NCT ID: NCT03419156 Recruiting - Clinical trials for Short Bowel Syndrome

Effect of a Short Message Service Intervention on Patients With Short Bowel Syndrome

Start date: February 20, 2018
Phase: N/A
Study type: Interventional

The investigators will be using a text messaging intervention to identify potentially dangerous and re- admission causing symptoms in patients with Short Bowel Syndrome (SBS) on Total Parenteral Nutrition (TPN). Each consented patient will receive weekly text messages inquiring about potentially harmful symptoms identified by a team of physicians. If the patient screens positive via text message, an alert will be sent to the medical team. All patients with SBS on TPN will receive text messages. The investigators will be monitoring response rates to text messages screening for potentially harmful symptoms and compare the text- message response rate to historical rates of successful calls by nurses. All patients with SBS on TPN will receive text messages instead of weekly phone calls from a nurse. If the patient does not respond to the text messages or the text message responses suggest that the patient may be presenting with potentially harmful symptoms, the nurse will call the patient to inquire about more information.

NCT ID: NCT03415594 Not yet recruiting - Clinical trials for Short Bowel Syndrome

Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support

Start date: February 28, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

once weekly dosing for 4 weeks in patients with short bowel syndrome who require total parenteral nutrition; patients will complete period 1 and after a 6-10 week wash-out, they will enter period 2 (active treatment and placebo)

NCT ID: NCT03408132 Not yet recruiting - Clinical trials for SBS - Short Bowel Syndrome

Metabolic Balance Study of FE203799 in Patients With SBS With Intestinal Insufficiency

Start date: February 28, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a repeated dose, open label trial investigating safety, efficacy, PD and PK of FE 203799 in 6 patients with SBS and intestinal insufficiency (SBS-II). The patients will receive a subcutaneous (SC) dose of 25 mg FE 203799 once weekly for 4 consecutive weeks, and efficacy parameters and PK will be assessed after the fourth dose. Safety follow up assessments will be performed 4-6 weeks after the last dose.